Brokerages Expect Heron Therapeutics Inc (NASDAQ:HRTX) Will Announce Earnings of -$0.60 Per Share
Equities analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will post earnings per share of ($0.60) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.67). Heron Therapeutics reported earnings of ($0.63) per share in the same quarter last year, which would indicate a positive year over year growth rate of 4.8%. The firm is scheduled to report its next earnings results on Monday, August 3rd.
According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($2.33) per share for the current year, with EPS estimates ranging from ($2.77) to ($1.41). For the next year, analysts anticipate that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($2.00) to $0.19. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.08. Heron Therapeutics had a negative net margin of 138.31% and a negative return on equity of 56.85%. The company had revenue of $25.40 million for the quarter, compared to analysts’ expectations of $21.23 million. During the same quarter in the previous year, the company posted ($0.80) EPS. The business’s revenue was down 19.6% compared to the same quarter last year.
NASDAQ HRTX traded up $0.70 during trading on Friday, reaching $15.12. The company’s stock had a trading volume of 744,921 shares, compared to its average volume of 1,281,861. The company has a current ratio of 4.53, a quick ratio of 4.17 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.32 billion, a PE ratio of -6.66 and a beta of 1.51. The business has a 50-day moving average price of $13.80 and a 200-day moving average price of $19.52. Heron Therapeutics has a 1-year low of $9.60 and a 1-year high of $26.81.
A number of large investors have recently added to or reduced their stakes in HRTX. Franklin Resources Inc. raised its stake in Heron Therapeutics by 19.6% during the 4th quarter. Franklin Resources Inc. now owns 12,361,411 shares of the biotechnology company’s stock valued at $290,496,000 after purchasing an additional 2,026,380 shares during the last quarter. Norges Bank acquired a new position in Heron Therapeutics during the 4th quarter valued at $23,384,000. Farallon Capital Management LLC acquired a new position in Heron Therapeutics during the 4th quarter valued at $20,563,000. Goldman Sachs Group Inc. raised its stake in Heron Therapeutics by 122.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,537,619 shares of the biotechnology company’s stock valued at $36,134,000 after purchasing an additional 847,578 shares during the last quarter. Finally, State Street Corp raised its stake in Heron Therapeutics by 24.4% during the 4th quarter. State Street Corp now owns 3,376,057 shares of the biotechnology company’s stock valued at $79,337,000 after purchasing an additional 663,063 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.